Risankizumab for treating moderately to severely active ulcerative colitis (TA998)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 August 2024
Mirikizumab for treating moderately to severely active Crohn's disease [ID6244]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 13 November 2024
Guselkumab for previously treated moderately to severely active Crohn's disease ID6238Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Guselkumab for treating moderately to severely active ulcerative colitis ID6237Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC